Monte Rosa Therapeutics Inc (NASDAQ:GLUE) — Market Cap & Net Worth
Market Cap & Net Worth: Monte Rosa Therapeutics Inc (GLUE)
Monte Rosa Therapeutics Inc (NASDAQ:GLUE) has a market capitalization of $1.39 Billion ($1.39 Billion) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #7398 globally and #2238 in its home market, demonstrating a -28.27% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Monte Rosa Therapeutics Inc's stock price $16.52 by its total outstanding shares 84382573 (84.38 Million). See Monte Rosa Therapeutics Inc capital reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
Monte Rosa Therapeutics Inc Market Cap History: 2021 to 2026
Monte Rosa Therapeutics Inc's market capitalization history from 2021 to 2026. Data shows change from $1.72 Billion to $1.39 Billion (-4.75% CAGR).
Index Memberships
Monte Rosa Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.06% | #215 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #825 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.72 Trillion | 0.08% | #130 of 263 |
Weight: Monte Rosa Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Monte Rosa Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Monte Rosa Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
10.70x
Monte Rosa Therapeutics Inc's market cap is 10.70 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $585.62 Million | $75.62 Million | -$72.70 Million | 7.74x | N/A |
| 2025 | $1.32 Billion | $123.67 Million | -$38.63 Million | 10.70x | N/A |
Competitor Companies of GLUE by Market Capitalization
Companies near Monte Rosa Therapeutics Inc in the global market cap rankings as of August 3, 2026.
Key companies related to Monte Rosa Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Monte Rosa Therapeutics Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Monte Rosa Therapeutics Inc's market cap moved from $1.72 Billion to $ 1.39 Billion, with a yearly change of -4.75%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.39 Billion | +5.36% |
| 2025 | $1.32 Billion | +125.94% |
| 2024 | $585.62 Million | +22.83% |
| 2023 | $476.76 Million | -25.76% |
| 2022 | $642.15 Million | -62.73% |
| 2021 | $1.72 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of Monte Rosa Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.39 Billion USD |
| MoneyControl | $1.39 Billion USD |
| MarketWatch | $1.39 Billion USD |
| marketcap.company | $1.39 Billion USD |
| Reuters | $1.39 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Monte Rosa Therapeutics Inc
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment… Read more